PTHS Pelthos Therapeutics Inc.

Price (delayed)

$25.87

Market cap

$89.91M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$21.85

Enterprise value

$110.62M

?
Relative Growth: Rel. Growth: 13
Relative Strength: Rel. Strength: 78
Relative Valuation: Rel. Valuation: 16
Relative Profitability: Rel. Profitability: 14

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as ...

Highlights
The gross profit has surged by 72% since the previous quarter
The quick ratio has surged by 71% since the previous quarter
The EPS has dropped by 77% year-on-year but it is up by 5% since the previous quarter
The company's debt has surged by 52% QoQ
PTHS's net income is down by 19% since the previous quarter

Key stats

What are the main financial stats of PTHS

PTHS stock price

How has the Pelthos Therapeutics stock price performed over time
Intraday
-0.04%
1 week
0.27%
1 month
4.23%
1 year
139.54%
YTD
-16.55%
QTD
23.13%

Financial performance

How have Pelthos Therapeutics's revenue and profit performed over time
Revenue
$27.7M
Gross profit
$22.04M
Operating income
-$43.68M
Net income
-$51.59M
Gross margin
79.6%
Net margin
-186.2%
The gross profit has surged by 72% since the previous quarter
The revenue has soared by 65% from the previous quarter
PTHS's operating income is down by 35% since the previous quarter
The company's net margin rose by 28% QoQ

Price vs fundamentals

How does PTHS's price correlate with its fundamentals

Growth

What is Pelthos Therapeutics's growth rate over time

Valuation

What is Pelthos Therapeutics stock price valuation
P/E
N/A
P/B
2.47
P/S
3.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.99
The EPS has dropped by 77% year-on-year but it is up by 5% since the previous quarter
The equity has declined by 10% since the previous quarter
The revenue has soared by 65% from the previous quarter

Efficiency

How efficient is Pelthos Therapeutics business performance
The ROA has soared by 88% YoY and by 24% from the previous quarter
The return on invested capital rose by 44% since the previous quarter
The ROS is up by 32% since the previous quarter
The return on equity has grown by 18% since the previous quarter

Dividends

What is PTHS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PTHS.

Financial health

How did Pelthos Therapeutics financials performed over time
PTHS's total assets is 32% higher than its total liabilities
The quick ratio has surged by 71% since the previous quarter
Pelthos Therapeutics's current ratio has increased by 36% QoQ
The company's debt is 51% higher than its equity
Pelthos Therapeutics's debt to equity has soared by 68% from the previous quarter
The company's debt has surged by 52% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.